NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Bratasz, Anna ^a   Selvendiran, Karuppaiyah ^a   Wasowicz, Tomasz ^a   Bobko, Andrey ^a   Khramtsov, Valery V ^a   Ignarro, Louis J ^b   Kuppusamy, Periannan ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ACETYLOXY)BENZOIC ACID 4 (NITROOXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; NCX 4040; NITRIC OXIDE; SERINE; STAT3 PROTEIN; THIOL; TYROSINE; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NITRO DERIVATIVE; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ELECTRON SPIN RESONANCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; STATISTICS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPIRIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NITRO COMPOUNDS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; SULFHYDRYL COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41049090416     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-9     Document Type: Article

References (58)

1. Harries M Gore M Part I: Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis Lancet Oncol 2002, 3(9):529-536. 10.1016/S1470-2045(02)00846-X 12217790
2. Harries M Gore M Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease Lancet Oncol 2002, 3(9):537-545. 10.1016/S1470-2045(02)00847-1 12217791
3. Yao X Panichpisal K Kurtzman N Nugent K Cisplatin nephrotoxicity: A review Am J Med Sci 2007, 334(2):115-124. 10.1097/MAJ.0b013e31812dfe1e 17700201
4. Screnci D McKeage MJ Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches J Inorg Biochem 1999, 77(1-2):105-110. 10.1016/S0162-0134(99)00135-X 10626361
5. Rybak LP Whitworth CA Mukherjea D Ramkumar V Mechanisms of cisplatin-induced ototoxicity and prevention Hear Res 2007, 226(1-2):157-167. 10.1016/j.heares.2006.09.015 17113254
6. Guastalla JP 3rd Dieras V The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer Br J Cancer 2003, 89 Suppl 3:S16-22. 10.1038/sj.bjc.6601496 14661042
7. Johnson SW Ozols RF Hamilton TC Mechanisms of drug resistance in ovarian cancer Cancer 1993, 71(2 Suppl):644-649. 8420689
8. Kartalou M Essigmann JM Mechanisms of resistance to cisplatin Mutat Res 2001, 478(1-2):23-43. 11406167
9. Agarwal R Kaye SB Ovarian cancer: Strategies for overcoming resistance to chemotherapy Nat Rev Cancer 2003, 3(7):502-516. 10.1038/nrc1123 12835670
10. Eastman A Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes Chem Biol Interact 1987, 61(3):241-248. 10.1016/0009-2797(87)90004-4 3568194
11. Ishikawa T The ATP-dependent glutathione S-conjugate export pump Trends Biochem Sci 1992, 17(11):463-468. 10.1016/0968-0004(92)90489-V 1455517
12. Rabik CA Dolan ME Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat Rev 2007, 33(1):9-23. 1855222 17084534 10.1016/j.ctrv.2006.09.006
13. Kelland L The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 2007, 7(8):573-584. 10.1038/nrc2167 17625587
14. Lewandowicz GM Britt P Elgie AW Williamson CJ Coley HM Hall AG Sargent JM Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer Gynecologic oncology 2002, 85(2):298-304. 10.1006/gyno.2002.6617 11972391
15. Liebmann JE Hahn SM Cook JA Lipschultz C Mitchell JB Kaufman DC Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity Cancer Res 1993, 53(9):2066-2070. 8097674
16. Rudin CM Yang Z Schumaker LM VanderWeele DJ Newkirk K Egorin MJ Zuhowski EG Cullen KJ Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance Cancer Res 2003, 63(2):312-318. 12543781
17. Schnelldorfer T Gansauge S Gansauge F Schlosser S Beger HG Nussler AK Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells Cancer 2000, 89(7):1440-1447. 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0 11013356
18. Bratasz A Weir NM Parinandi NL Zweier JL Sridhar R Ignarro LJ Kuppusamy P Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin Proc Natl Acad Sci U S A 2006, 103(10):3914-3919. 1450164 16497833 10.1073/pnas.0511250103
19. Selvendiran K Bratasz A Tong L Ignarro LJ Kuppusamy P NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts Cell Cycle 2008, 7(1):81-88. 18196976
20. Gao J Kashfi K Rigas B In vitro metabolism of nitric oxide-donating aspirin: The effect of positional isomerism J Pharmacol Exp Ther 2005, 312(3):989-997. 10.1124/jpet.104.076190 15528452
21. Rosetti M Tesei A Ulivi P Fabbri F Vannini I Brigliadori G Amadori D Bolla M Zoli W Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines Apoptosis 2006, 11(8):1321-1330. 10.1007/s10495-006-6986-x 16699954
22. Fabbri F Brigliadori G Ulivi P Tesei A Vannini I Rosetti M Bravaccini S Amadori D Bolla M Zoli W Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells Apoptosis 2005, 10(5):1095-1103. 10.1007/s10495-005-0619-7 16151642
23. Leonetti C Scarsella M Zupi G Zoli W Amadori D Medri L Fabbri F Rosetti M Ulivi P Cecconetto L Bolla M Tesei A Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts Mol Cancer Ther 2006, 5(4):919-926. 10.1158/1535-7163.MCT-05-0536 16648562
24. Tesei A Ulivi P Fabbri F Rosetti M Leonetti C Scarsella M Zupi G Amadori D Bolla M Zoli W In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines J Transl Med 2005, 3(1):7. 549525 15691389 10.1186/1479-5876-3-7
25. Tesei A Rosetti M Ulivi P Fabbri F Medri L Vannini I Bolla M Amadori D Zoli W Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines J Transl Med 2007, 5(1):52. 2174440 17971198 10.1186/1479-5876-5-52
26. Kashfi K Borgo S Williams JL Chen J Gao J Glekas A Benedini F Del Soldato P Rigas B Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo J Pharmacol Exp Ther 2005, 312(3):978-988. 10.1124/ jpet.104.075994 15528453
27. Khramtsov VV Yelinova VI Glazachev Yu I Reznikov VA Zimmer G Quantitative determination and reversible modification of thiols using imidazolidine biradical disulfide label J Biochem Biophys Methods 1997, 35(2):115-128. 10.1016/S0165-022X(97)00035-3 9350517
28. Kuppusamy P Wang P Samouilov A Zweier JL Spatial mapping of nitric oxide generation in the ischemic heart using electron paramagnetic resonance imaging Magn Reson Med 1996, 36(2):212-218. 10.1002/mrm.1910360207 8843374
29. Andrews PA Jones JA Varki NM Howell SB Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma Cancer communications 1990, 2(2):93-100. 2372473
30. Kern DH Morgan CR Hildebrand-Zanki SU In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: Synergy of antitumor activity with cis-diamminedichloroplatinum(II) Cancer Res 1988, 48(1):117-121. 3334986
31. Khramtsov VV Yelinova VI Weiner LM Berezina TA Martin VV Volodarsky LB Quantitative determination of SH groups in low- and high-molecular-weight compounds by an electron spin resonance method Anal Biochem 1989, 182(1):58-63. 10.1016/0003-2697(89)90718-5 2557778
32. Kuppusamy P Afeworki M Shankar RA Coffin D Krishna MC Hahn SM Mitchell JB Zweier JL In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model Cancer Res 1998, 58(7):1562-1568. 9537265
33. Ilangovan G Bratasz A Li H Schmalbrock P Zweier JL Kuppusamy P In vivo measurement and imaging of tumor oxygenation using coembedded paramagnetic particulates Magn Reson Med 2004, 52(3):650-657. 10.1002/ mrm.20188 15334586
34. Komarov A Mattson D Jones MM Singh PK Lai CS In vivo spin trapping of nitric oxide in mice Biochem Biophys Res Commun 1993, 195(3):1191-1198. 10.1006/bbrc.1993.2170 8216248
35. Kuppusamy P Li H Ilangovan G Cardounel AJ Zweier JL Yamada K Krishna MC Mitchell JB Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels Cancer Res 2002, 62(1):307-312. 11782393
36. del Soldato P Sorrentino R Pinto A NO-aspirins: A class of new anti-inflammatory and antithrombotic agents Trends Pharmacol Sci 1999, 20(8):319-323. 10.1016/S0165-6147(99)01353-X 10431210
37. Cohen SM Lippard SJ Cisplatin: From DNA damage to cancer chemotherapy Prog Nucleic Acid Res Mol Biol 2001, 67:93-130. 11525387
38. Nishimura T Newkirk K Sessions RB Andrews PA Trock BJ Rasmussen AA Montgomery EA Bischoff EK Cullen KJ Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer Clin Cancer Res 1996, 2(11):1859-1865. 9816141
39. Shiga H Heath EI Rasmussen AA Trock B Johnston PG Forastiere AA Langmacher M Baylor A Lee M Cullen KJ Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer Clin Cancer Res 1999, 5(12):4097-4104. 10632346
40. Nishimura T Newkirk K Sessions RB Andrews PA Trock BJ Rusmussen AA Montogomery EA Bischoff EK Hanigan MH Cullen KJ Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer Chem Biol Interact 1998, 111-112:187-198. 10.1016/S0009-2797(97)00161-0 9679554
41. Hockenbery DM Oltvai ZN Yin XM Milliman CL Korsmeyer SJ Bcl-2 functions in an antioxidant pathway to prevent apoptosis Cell 1993, 75(2):241-251. 10.1016/0092-8674(93)80066-N 7503812
42. Clancy RM Levartovsky D Leszczynska-Piziak J Yegudin J Abramson SB Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: Evidence for S-nitrosoglutathione as a bioactive intermediary Proc Natl Acad Sci U S A 1994, 91(9):3680-3684. 43645 8170969 10.1073/pnas.91.9.3680
43. Clark AG Debnam P Inhibition of glutathione S-transferases from rat liver by S-nitroso-L-glutathione Biochem Pharmacol 1988, 37(16):3199-3201. 10.1016/0006-2952(88)90321-8 3401252
44. Becker K Gui M Schirmer RH Inhibition of human glutathione reductase by S-nitrosoglutathione Eur J Biochem 1995, 234(2):472-478. 10.1111/ j.1432-1033.1995.472_b.x 8536691
45. Hulsman N Medema JP Bos C Jongejan A Leurs R Smit MJ de Esch IJ Richel D Wijtmans M Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin J Med Chem 2007, 50(10):2424-2431. 10.1021/jm061371e 17441704
46. Kashfi K Rigas B The mechanism of action of nitric oxide-donating aspirin Biochem Biophys Res Commun 2007, 358(4):1096-1101. 10.1016/ j.bbrc.2007.05.038 17512900
47. Dunlap T Chandrasena RE Wang Z Sinha V Wang Z Thatcher GR Quinone formation as a chemoprevention strategy for hybrid drugs: Balancing cytotoxicity and cytoprotection Chem Res Toxicol 2007, 20(12):1903-1912. 10.1021/tx7002257 17975886
48. Salomon DS Brandt R Ciardiello F Normanno N Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 1995, 19(3):183-232. 10.1016/1040-8428(94)00144-I 7612182
49. Coley HM Shotton CF Ajose-Adeogun A Modjtahedi H Thomas H Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents Biochem Pharmacol 2006, 72(8):941-948. 10.1016/j.bcp.2006.07.022 16934227
50. Woodworth CD Michael E Marker D Allen S Smith L Nees M Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment Mol Cancer Ther 2005, 4(4):650-658. 10.1158/1535-7163.MCT-04-0238 15827339
51. Duan Z Foster R Bell DA Mahoney J Wolak K Vaidya A Hampel C Lee H Seiden MV Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer Clin Cancer Res 2006, 12(17):5055-5063. 10.1158/1078-0432.CCR-06-0861 16951221
52. Lo HW Hsu SC Ali-Seyed M Gunduz M Xia W Wei Y Bartholomeusz G Shih JY Hung MC Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway Cancer Cell 2005, 7(6):575-589. 10.1016/ j.ccr.2005.05.007 15950906
53. Bhardwaj A Sethi G Vadhan-Raj S Bueso-Ramos C Takada Y Gaur U Nair AS Shishodia S Aggarwal BB Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells Blood 2007, 109(6):2293-2302. 10.1182/blood-2006-02-003988 17164350
54. Choudhari SR Khan MA Harris G Picker D Jacob GS Block T Shailubhai K Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod Mol Cancer Ther 2007, 6(1):112-121. 10.1158/1535-7163.MCT-06-0561 17237271
55. Selvendiran K Koga H Ueno T Yoshida T Maeyama M Torimura T Yano H Kojiro M Sata M Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids Cancer Res 2006, 66(9):4826-4834. 10.1158/0008-5472.CAN-05-4062 16651438
56. Torroglosa A Murillo-Carretero M Romero-Grimaldi C Matarredona ER Campos-Caro A Estrada C Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway Stem cells (Dayton, Ohio) 2007, 25(1):88-97. 10.1634/stemcells.2006-0131 16960136
57. Rieder J Jahnke R Schloesser M Seibel M Czechowski M Marth C Hoffmann G Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines Gynecologic oncology 2001, 82(1):172-176. 10.1006/gyno.2001.6242 11426981
58. Yu H Jove R The STATs of cancer - new molecular targets come of age Nat Rev Cancer 2004, 4(2):97-105. 14964307